Assessment of the adverse effects of sirolimus versus everolimus in pediatric heart transplant recipients.
David M NewlandBeatrice E HoYuk M LawMariska S KemnaErin L AlbersBorah J HongHumera AhmedKathryn L SpencerJoshua M Friedland-LittlePublished in: Pediatric transplantation (2023)
Low-dose PSIs in calcineurin inhibitor minimization regimens appear well-tolerated with low withdrawal rate secondary to AE in pediatric HTx recipients. While incidence of most AE was similar between PSI, our results suggest EVL may be associated with less favorable metabolic impact than SRL in this population.